# OnCo record nct03190941 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03190941/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03190941", "NCT03190941" ;
  schema:name "Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients"@en ;
  schema:description "A phase 1/2 trial of cyclophosphamide, fludarabine and aldesleukin (high-dose IL-2) in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03190941/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03190941> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "pancreatic-deep-dive" ;
  onco:phase "1/2" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/fludarabine/>, <https://onco.cc/drugs/aldesleukin/> .